Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Raf-1 is a proto-oncogene serine/threonine protein kinase that signals from Ras to the MAPK/ERK signaling pathway. This pathway mediates basic cellular functions, including proliferation, differentiation, and survival. GW 5074 is a potent, selective, and cell-permeable inhibitor of Raf-1 (IC50 = 9 nM). It blocks phosphorylation of ERK1/2 by 90% in cells stimulated with epidermal growth factor when given at 5 µM. GW 5074 shows more than 100-fold selectivity for Raf-1 versus several related kinases.
GW 5074 is supplied as a crystalline solid. A stock solution may be made by dissolving the GW 5074 in the solvent of choice. GW 5074 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of GW 5074 in these solvents is approximately 15 mg/ml. GW 5074 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GW 5074 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. GW 5074 has a solubility of approximately 0.1 mg/ml in a 1:8 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Dhillon, A.S. and Kolch, W. Untying the regulation of the Raf-1 kinase. Arch. Biochem. Biophys. 404, 3-9 (2002).
Kunnimalaiyaan, M. and Chen, H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17, 139-142 (2006).
Lackey, K., Cory, M., David, R., et al. The discovery of potent cRaf1 kinase inhibitors. Bioorg. Med. Chem. Lett. 10(3), 223-226 (2000).